Ge Long Hui A P P·2026-02-02 07:35Core Viewpoint - Dongsheng Pharmaceutical has a solid foundation in traditional Chinese medicine and is entering a harvest period for its innovative pipeline, with a multi-layered R&D system based on specialty traditional Chinese medicine, high-end generic drugs, and innovative drugs [1] Group 1: Product Development and Market Position - Several key products have entered commercialization or late-stage clinical trials in recent years [1] - The PB2-targeted RNA polymerase inhibitor, Anladiwei tablets, for treating adult uncomplicated influenza A, is expected to be approved for market launch in May 2025, showing competitive advantages over Oseltamivir in Phase III clinical data [1] - The core product, Compound Xuehuo Tong capsules, is a unique original formulation that has ranked first in market share for oral traditional Chinese medicine in the ophthalmology field for several consecutive years [1] Group 2: Market Outlook and Financial Projections - As the impact of centralized procurement gradually dissipates, sales are expected to stabilize and recover [1] - The company is optimistic about the dual-driven growth of traditional Chinese medicine and chemical drugs, with the latter's innovative clinical pipeline entering late stages [1] - The company has significant potential for large products and international expansion, with a target price of 23.37 yuan based on a 57x PE ratio for 2026, reflecting the industry average [1]